Metric was founded by physicists, biologists, and machine learning researchers with backgrounds at Columbia and Caltech. Together, the team brings decades of experience in biophysics, experimental biology, and large-scale machine learning systems.
We are building toward lead-independent, single-cycle molecular discovery. Our goal is to start with a target and molecular profile, learn the interaction through one information-rich pooled campaign, and reach a validated candidate panel without a supplied lead.
One cycle consists of one pooled campaign followed by one locked validation panel.
Frontier molecular AI is becoming increasingly capable at proposing plausible binders. High-throughput experiments can now measure target-specific interactions across enormous sequence spaces. Metric connects those advances through biophysical modeling and target-specific training.
Peer-reviewed work by members of the founding team established the core inference principle behind Metric. Since the 2022 publication, we have built a proprietary target-trained molecular design platform that extends the work across campaign design, assay-aware modeling, molecular search, and validation.
We are now applying the platform with biopharmaceutical innovators across immunology and oncology, including a leader in TCR–pMHC therapeutics.